Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 9/20 | 0.39 |
| ▸ | CA2 | P00918 | 9/20 | 0.39 |
| ▸ | CA9 | Q16790 | 9/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1060280 | 0.83 | AAK1 (0.39) | NPC1CA1CA2CA9ALDH1A1 | |
| SCHEMBL2292922 | 0.82 | HIF1A (0.41) | NPC1ALDH1A1MAPTRAB9AGAA | |
| SCHEMBL1061781 | 0.80 | POLB (0.40) | ALDH1A1LMNAGAA | |
| SCHEMBL1675460 | 0.79 | ALDH1A1 (0.43) | ALDH1A1MAPTLMNA | |
| SCHEMBL1675461 | 0.79 | ALDH1A1 (0.43) | ALDH1A1MAPTLMNA | |
| SCHEMBL29421539 | 0.79 | G6PD (0.37) | CA1CA2CA9LMNA | |
| SCHEMBL395845 | 0.79 | G6PD (0.37) | CA1CA2CA9LMNA | |
| SCHEMBL2294873 | 0.77 | UCHL1 (0.42) | ALDH1A1MAPTGAA | |
| SCHEMBL25427514 | 0.76 | KMT2A (0.39) | ALDH1A1MAPT | |
| SCHEMBL16735793 | 0.76 | LIPE (0.47) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180333406-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2018-11-22 | — | — | US | disclosed |
| EP-2268618-B1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2015-05-27 | — | — | EP | disclosed |
| EP-2512478-A1 | HOMOGENEOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| EP-2440245-A1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | Novartis AG (CH) | 2012-04-18 | — | — | EP | disclosed |
| WO-2011084549-A1 | HOMOGENEOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2011-07-14 | — | — | WO | disclosed |
| WO-2010144734-A1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | NOVARTIS AG (CH) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180333406-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | HAMP, MAVS, MYD88 | NPC1 3418/4885CA1 4263/4885CA2 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.